May 02, 2025, 14:27 ET Novo Nordisk hopes to expand Wegovy label by becoming the first GLP-1 treatment for obesity in a pill The FDA filing is based on the results of the phase 3 OASIS 4 trial that evaluated oral semaglutide 25 mg in adults with obesity or overweight 1 Novo Nordisk continues to build on 100-year-plus legacy of science and innovation PLAINSBORO, N.J., May 2, 2025 /PRNewswire/ -- Today, Novo Nordisk announced that the U.S
They can adjust your dose schedule, hold the dose at the current level, or recommend an alternative treatment
N.WilliamsT
While Ozempic has positive effects, all medications can have less favorable side effects
These vitamin injections are critical for so many diverse things
You should consult your healthcare provider to see if an alternate diabetes medication is needed, says Eapen, MD